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ABSTRACT
In order to reduce the cost of vaccination, three herds were vaccinated with polyvalent bovine viral 
diarrhea virus inactivated vaccine according to a modifi ed schedule, and the specifi c antibody response was 
evaluated. In each herd only the cows and heifers were vaccinated with one dose of vaccine. Two herds (A and 
B) were vaccinated annually for three consecutive years. The third herd (C) was vaccinated twice with a two 
year interval. At the beginning of the study the herds consisted of 38, 22 and 15 animals respectively. Antibody 
response was evaluated three and nine months after vaccination with indirect ELISA, blocking ELISA and 
a virus neutralization test. Within herds A and B the percentage of seropositive animals increased with each 
subsequent vaccination. Three months after the third vaccination more than 96% of animals in herds A and B 
were seropositive. Nine months after the third vaccination more than 56% of animals in herds A and B were 
seropositive. Three and nine months after the second vaccination the numbers of positive animals in herd C 
was 66% and 38% respectively. The obtained results show that the percentage of seropositive animals within 
the herds increased with each vaccination and the best detection of specifi c antibodies after vaccination can 
be achieved if a virus neutralization test is used. Also, the results show that seroprotection of cows within the 
herds vaccinated yearly was signifi cantly higher (56.52-58.82%) compared to the herd vaccinated with a two 
year interval (38.88%). 
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Introduction 
Bovine viral diarrhea virus (BVDV) is one of the most important common viral 
infections in cattle (HOUE, 1999). BVDV belongs to the genus Pestivirus within the 
Flaviviridae family (SIMMONDS et al., 2012). Due to the economic losses caused by 
BVDV, some countries have implemented control and eradication programs. 
Vaccination is currently one of the control procedures for BVDV in stocker and 
feedlot operations (FULTON, 2005). Vaccines are based on either BVDV alone or BVDV 
in combination with bovine herpesvirus-1, parainfl uenza virus type 3, bovine respiratory 
syncytial virus and bacteria (FULTON, 2005). Currently two types of vaccines are 
commercially present on the market within EU countries: a modifi ed live vaccine (MLV) 
and a killed vaccine. MLV requires a smaller quantity of virus than the killed one, and 
only one dose for initial immunization (FULTON, 2005). However, the live virus in the 
modifi ed live BVDV vaccine can cause immunosuppressive effects on leukocyte function 
(ROTH and KAEBERLE, 1983). A major concern in the use of BVDV MLV is postvaccinal 
disease (mucosal disease) following MLV vaccination (RIDPATH and BOLIN, 1995). Killed 
vaccines are generally safer in pregnant cows, but a disadvantage might be that two doses 
are generally required for the initial immunization (FULTON, 2005).
In order to achieve a better specifi c antibody response, especially when an inactivated 
vaccine is used, a booster vaccination is applied. This is particularly important in 
vaccination of calves due to their passive immunity. In that case MLV is also used; 
one or even two booster vaccinations are needed to achieve a higher titer of specifi c 
antibodies. However, even in this case it is not always possible to achieve a protective 
level of antibodies regarding transmission of the virus to the fetus. As a result, the main 
purpose of vaccination is prevention of acute infection. Also, even true protection against 
infection cannot be determined by merely measuring serum antibody levels (CORTESE et 
al., 1998; RIDPATH, 2003) although this is still the most rapid and cost effective method for 
detection of exposure to BVDV. The duration of antibody titers to various BVDV strains 
in calves was found to vary from 140 days to 18 months after vaccination (CORTESE et 
al., 1998; FULTON and BURGE, 2000).
In determination of BVDV antibodies, the most used method is ELISA because of its 
simplicity and time consumptions. Two types of ELISA kits are currently used: indirect 
and blocking (p80) ELISA. However, blocking ELISA is less suitable in detection of 
specifi c antibodies after vaccination (GRAHAM et al., 2003).
In order to determine protection and cost benefi ts, effi ciency should be measured 
by fi eld trial for each vaccine. Due to the diversity of the BVDV genotype, it is very 
diffi cult to accomplish 100% protection by vaccination, especially from the development 
of persistent infection. Despite that, vaccination is still the most used tool in control 
and eradication programs, and in prevention of acute infection. In voluntary control 
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vaccination programs the main reason for refusing vaccination is the price of both the 
vaccine and the vaccination. The use of a polyvalent vaccine can contribute to the lower 
cost of vaccination. On the other hand, the use of a polyvalent vaccine can result in 
lower immunity response compared to a single vaccination. In addition, the possibility 
of vaccinating all animals within the herd in one day can signifi cantly lower the price of 
vaccination. 
In this study, we investigated the possibility of protecting herds against BVDV with 
a lower number of vaccinations and lower cost. To achieve this, a modifi ed schedule 
of vaccination with polyvalent BVDV inactivated vaccine was implemented, and 
specifi c BVDV antibody response was evaluated. Antibody response after vaccination 
was determined by indirect ELISA (iELISA), blocking ELISA (bELISA) and a virus 
neutralization test (VNT). Also, evaluation was undertaken of iELISA and bELISA 
compared to VNT in detection of specifi c antibodies after vaccination. 
Materials and methods
Field study. Three seronegative BVDV herds of Simmental breed cows were selected 
for this study. After the beginning of the study, the introduction of new animals was 
restricted. All three herds were dairy herds. At the start of the study, herd A consisted of 
38 cattle, of which 30 were older than 6 months. Herd B consisted of 22 cattle, with 18 
older than 6 months. Herd C consisted of 15 cattle, with 12 older than 6 months. This 
study was approved by the ethics committee of the Veterinary Faculty of the University 
of Zagreb; number: 251-61-01/139-11-72.
Experimental design. All animals older than six months within the three herds were 
vaccinated with polyvalent inactivated BVDV vaccine (Cattle Master, Pfi zer). Two herds 
(A and B) were vaccinated in 2008, 2009 and 2010. Herd C was vaccinated in 2008 
and 2010. In each herd, all heifers and cows (all animals older than six months) were 
vaccinated at the same time. For each vaccination, only one dose of vaccine was applied. 
No booster vaccination was conducted. Calves were not vaccinated. However, each calf 
was vaccinated when it had reached the age of 6 months (when they became heifers) 
by the time of the next vaccination. At the beginning of this study three calves were 
randomly selected from each herd and were used as a control group. These calves stayed 
in the herd throughout the study and were not vaccinated. These calves were not included 
in the statistical analysis. 
Sampling. Blood samples were taken on the day of vaccination. From herds A and B 
blood samples were also taken three and nine months after each vaccination. From herd 
C blood samples were taken three, nine, 15 and 21 months after the fi rst vaccination and 
three and nine months after the second vaccination. 
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 Virus testing. In order to obtain virus status, all samples were tested for virus presence 
by antigen enzyme-immunosorbent assay (Herdchek BVDV Ag/Serum Plus, IDEXX, 
Switzerland). Sera were tested according to the manufacturer’s recommendations.
Antibody testing. Antibody response against BVDV was determined using two 
commercial ELISA kits and a virus neutralization test. The following commercial ELISA 
kits were used: Herd Check BVDV Ab (IDEXX, Switzerland) and PrioCHECK BVDV 
Ab (Prionics, Switzerland). Tests were performed according to the manufacturers’ 
recommendations. The virus neutralization test was performed according to the Manual 
for Terrestrial Animals (OIE, 2008). Briefl y, sera were inactivated at 56 °C for 30 min. 
Two-fold serial dilutions of sera ranging from 1:2 to 1:256 were made in microtiter plates. 
For each reference strain, two wells were used. One hundred TCID50 of the reference 
strains (NADL - supplied by Friedrich Loeffl er Institute, Insel Riems, Germany) were 
added to duplicate columns. In Croatia only genotype 1 has been confi rmed and as a result 
the antibody response was determined only against genotype 1. After 1 hour of incubation 
at 37 °C, Madin Darby bovine kidney cells were added and the plates were incubated 
for four days at 37 °C. After incubation, the presence of viruses was confi rmed using 
BVDV specifi c monoclonal antibodies (BVDV specifi c monoclonal antibodies, VLA, 
Weybridge, UK) and antimouse rabbit antibodies (Fluorescein isothiocyanate conjugate 
anti-mouse antibodies, Sigma-Aldrich, St.Louis, USA). Even though NADL strain is a 
cytopathic strain, immunofl uorescence staining was applied. The reason for this is the 
possibility of differentiation between citotoxicity in the cell culture and positive results, 
especially at lower dilutions. Antibody titers of 1:2 and higher were considered positive.
All calves in the control group stay seronegative throughout the study. 
Statistic analysis. Sensitivity and specifi city were calculated using the following 
formula: sensitivity = [true positives/(true positives + false negatives)]  100; specifi city: 
true negative/(true negatives + false positives)  100. 
Results
Virus testing. All herds remained negative for the virus throughout the study.
Antibody testing. At the beginning of the study all the animals were seronegative 
for antibodies against BVDV when tested by VNT and both ELISA kits: Herd Check 
BVDV Ab (IDEXX, Switzerland) and PrioCHECK BVDV Ab (Prionics, Switzerland). 
Three and nine months after the fi rst vaccination in herd A immunity tested by VNT 
was 68.42% and 39.47% respectively. After the second vaccination the immunity of 
the herd tested by VNT was 83.33% and 58.82%. After the third vaccination immunity 
was 95% and 60%. Antibody response within herd A in vaccinated cattle and data about 
colostrum antibodies within calves are presented in Table 1. Three and nine months after 
the fi rst vaccination in herd B immunity was 59.09% and 40% respectively. After the 
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second vaccination immunity was 79.16% and 52%. After the third vaccination immunity 
was 92.85% and 56%. Antibody response within herd B in vaccinated cattle and data 
about colostrum antibodies in calves are presented in Table 2. Three and nine months 
after the fi rst vaccination, in herd C immunity was 60% and 38.46% respectively. 15 
and 21 months after the fi rst vaccination immunity was 26.66% and 16.66%. After the 
second vaccination immunity was 65% and 38.88%. Antibody response within herd C in 
vaccinated cattle and data about colostrums antibodies in calves are presented in Table 3. 
The specifi city and sensitivity of iELISA and bELISA compared to VNT were calculated 
for each herd.
Table 1. The number of positive animals within herd A three and nine months after the fi rst, 
second and third vaccinations 
Cows and heifers Calves
Time of 
sampling iELISA bELISA VNT iELISA bELISA VNT
1st vacc.
3 months 13/30 3/30 26/30 0/8 0/8 0/8
9 months 6/30 1/30 15/30 0/8 0/8 0/8
2nd vacc.
3 months 23/30 4/30 28/30 1/6 0/6 2/6
9 months 9/28 2/28 17/28 2/6 0/6 3/6
3rd vacc.
3 months 32/36 5/36 36/36 2/4 1/4 2/4
9 months 11/34 1/34 20/34 2/6 0/6 4/6
Table 2. The number of positive animals within herd B three and nine months after the fi rst, 
second and third vaccinations 
         Cows and heifers Calves
Time of 
sampling iELISA bELISA VNT iELISA bELISA VNT 
1st vacc.
3 months 6/18 1/18 13/18 0/4 0/4 0/4
9 months 2/18 0/18 8/18 0/2 0/2 0/2
2nd vacc.
3 months 14/22 3/22 17/22 1/2 0/2 2/2
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9 months 5/22 1/22 10/22 0/3 0/3 3/3
3rd vacc.
3 months 21/26 4/26 25/26 0/2 0/2 1/2
9 months 7/23 0/23 13/23 1/2 1/2 1/2
Table 3. The number of positive animals within herd C three, nine, fi fteen and twenty-one months 
after the fi rst vaccination; and three and nine months after the second vaccination 
          Cows and heifers Calves
Time of 
sampling iELISA bELISA VNT iELISA bELISA VNT 
1st vacc. 
3 months 4/12 2/12 9/12 0/3 0/3 0/3
9 months 2/11 0/11 5/11 0/2 0/2 0/2
15 months 2/14 0/14 4/14 0/1 0/1 0/1
21 months 1/15 0/15 3/15 0/3 0/3 0/3
2nd vacc. 
3 months 4/18 1/18 12/18 1/2 0/2 1/2
9 months 3/18 0/18 7/18 0/0 0/0 0/0
Statistical analysis The sensitivity and specifi city of indirect and blocking ELISA 
compared to VNT are presented in Table 4. 
Table 4. The sensitivity and specifi city of indirect ELISA (iELISA) and blocking ELISA 
(bELISA) within herds compared to the virus neutralization test (VNT)
 Herd
iELISA bELISA
Sensitivity (%) Specifi city (%) Sensitivity (%) Specifi city (%)
A 74.63 100 52.94 100
B 62.33 100 51.79 100
C 63.07 100 51.89 100
Discussion 
Vaccination is still the most commonly used tool in BVDV control and eradication 
programs. Two different vaccines are currently used against BVDV: live modifi ed and 
inactivated vaccine. Due to the applicability BVD vaccine is very often used as part 
of polyvalent vaccines. The assessment of vaccine quality includes several points 
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(FULTON, 2005). These include a fi eld study and a cost benefi t study. The fi eld study 
includes assessment of antibody response and a challenge trial. Even though it does not 
have absolute value, determination of specifi c antibodies is still the most common and 
economically most effective method for evaluation of exposure to BVDV. In that sense, 
it is very important to have good diagnostic tools. In determination of BVDV specifi c 
antibodies, the most frequently used method is ELISA because of its simplicity and 
duration. Two types of ELISA kits are currently used: indirect and blocking (p80) ELISA. 
It has been reported that some, but not all, inactivated BVDV vaccines do not induce 
detectable antibodies against the NS3 (p80) protein (GRAHAM et al., 2003). These fi ndings 
were confi rmed in other studies (ALVAREZ et al., 2012; MAKOSCHEY et al., 2007; RAUE et 
al., 2010). According to previous studies, indirect ELISA was very good in the detection 
of BVDV antibodies after vaccination (RAUE et al., 2010). According to the manufacturer, 
the specifi city and sensitivity of iELISA kit are 99.5% and 96.3% compared to VNT. 
In our case the sensitivity and specifi city of indirect ELISA was 71.92% and 100% 
compared to VNT. The sensitivity and specifi city of bELISA was 52.75% and 100%. Due 
to its high cost VNT is rarely used for evaluation of specifi c BVDV antibody response 
after vaccination. However, our fi ndings implicate that only VNT can provide accurate 
assessment of antibody response after vaccination. 
In vaccination against BVDV different protocols are used. The protocol depends 
on the production type. The standard protocol of vaccination of dairy herds includes 
vaccination of calves and annual vaccination of heifers and cow. The vaccination of 
calves includes two or three vaccinations with three week intervals depending on 
the age at the fi rst vaccination. Vaccination of heifers includes a fi rst vaccination and 
booster vaccinations three weeks and six months after the fi rst one. With this vaccination 
schedule, three weeks after the second vaccination all animals were positive for BVDV 
antibodies (ALVAREZ et al., 2012). However, for cattle as herd animals herd immunity is 
very important. Herd immunity implies that overall immunity of the herd is greater than 
the sum of immunity enjoyed by individual animals in the herd (THURMOND, 2005). 
Furthermore, immunity to most infectious agents is not likely to be absolute (THURMOND, 
2005). This is particularly true in the case of BVDV because of the presence of high 
antigenic diversity among BVDV strains (DUBOVI, 1992; RIDPATH et al., 2003) and the 
possibility of persistent infection. Also, booster vaccinations affect the fi nal price and 
the cost benefi ts of vaccination. Ideally, satisfactory protection of the herd is achieved 
with a minimal number of vaccination. However, BVD is a specifi c disease because of 
persistent infection, and implementation of vaccination without other measures (culling 
of persistently infected animals) is not suffi cient for eradication of the disease. 
One approach to estimating the rate of force of transmission and herd immunity is 
the use of a basic reproduction number (R0), referred to as R-not, which represents the 
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expected number of new infections resulting from contact with an infectious index case 
animal (THURMOND, 2005). The R-not depends on the infectiousness of the virus strain 
(β), the number of adequate contacts per time period (k) and the duration of the infectious 
period. If R0 is 4 then the proportion of the herd that will need to be effectively immunized 
by vaccination to prevent transmission from acutely infected animals is 75%. If the R0 
is 2, rather than 4, only 50% of the herd would need to be immunized (THURMOND, 
2005). Experience has shown that vaccination is not suffi cient for elimination of persistent 
infection from the herd. However, with vaccination, acute infection can be reduced. In 
the case of acute infection R0 can be calculated. Let us suppose that the incidence is 
0.5% per day for weaned calves (RUSH et al., 2001), k is about 25 contacts per day, and 
the prevalence of PI animals is 1%, and β is 0.02. After substituting this value into the 
formula for R0 and assuming an infectious period of 4 days, R0 = 2. This means that acute 
infection can be prevented if 50% of herd is protected. 
In our study, three months after the fi rst vaccination, more than 50% of animals were 
positive for specifi c antibodies. Nine months after the fi rst vaccination in herds A and B 
around 40% of animals were positive for specifi c antibodies. However, after the second 
and third vaccinations, the number of positive animals within the herd increased. Three 
months after the third vaccination, in herds A and B the number of positive animals was 
95% and 92% respectively. Nine months after the third vaccination, in herds A and B 
the number of positive animals was 60% and 56% respectively. This implies that the 
duration of immunity in vaccinated cattle is an individual characteristic. Also, not only 
did the number of positive animals fall after nine months, but the level of antibodies 
also decreased within some positive animals (data are not shown). The infl uence of 
the decreasing protective antibody levels should be further evaluated by a challenge 
trial. This is particularly true if it is known that in some cases vaccinated animals 
without measurable antibodies were protected after a challenge (CORTESE et al., 1998). 
Nevertheless, continual annual vaccination of heifers and cows in dairy herds has the 
potential to provide satisfactory immunity of the herd. Furthermore, with this vaccination 
schedule each heifer will be vaccinated before breeding. This is very important because 
of the possibility of establishment of persistent infection.
 In herd C antibody levels did not increase after the second vaccination. Also, the 
number of positive animals two years after vaccination was below 50%. However, 
even after 21 months antibodies were detected in some animals. This indicated that this 
schedule of vaccination is not applicable to herd protection. In addition, this fi nding 
confi rms individual differences in the duration of immunity. 
In conclusion, the response of specifi c BVDV antibodies after vaccination using 
a modifi ed schedule was very good. According to this schedule each heifer will be 
vaccinated before breeding in order to prevent persistent infection. After the second 
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vaccination the level of herd immunity did not drop below 50% for one year. Moreover, 
after each subsequent vaccination the percentage of positive animals increased. This 
schedule of vaccination shows that it can provide identical protection after infection with 
BVDV as a standard scheme, but with lower cost. However, further studies, especially 
a challenge trial, are needed to confi rm that possibility. Also, it should be noted that this 
vaccine does not provide foetal protection even after vaccination according to the regular 
schedule. According to this study for assessment of antibody response after vaccination, 
VNT should be used.
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SAŽETAK
Da bi se procijenila mogućnost smanjenja troškova cijepljenja, tri su stada goveda cijepljena protiv 
virusnog proljeva goveda polivalentnim cjepivom prema modifi ciranoj shemi. U dva stada (38 i 22 goveda) 
sve krave i junice cijepljene su jednom godišnje tri godine uzastopce. U trećem stadu (15 goveda) cijepljene 
su sve krave i junice prve i treće godine. Uspješnost cijepljenja provjeravala se imunoenzimnim testom i virus-
neutralizacijskim testom određujući specifi čna protutijela u uzorcima krvnih seruma. Tri mjeseca nakon trećeg 
cijepljenja unutar prva dva stada postotak serološki pozitivnih goveda bio je veći od 96%. Devet mjeseci nakon 
trećeg cijepljenja unutar prva dva stada postotak serološki pozitivnih goveda bio je veći od 56%. U trećem stadu 
postotak serološki pozitivnih goveda tri i devet mjeseci nakon trećeg cijepljenja bio je 66% i 38%. Dobiveni 
rezultati pokazuju da se postotak serološki pozitivnih grla unutar svakog stada svakim sljedećim cijepljenjem 
povećao te da se procjena uspješnosti cijepljenja najbolje može odrediti virus-neutralizacijskim testom.
Ključne riječi: virusni proljev goveda, cijepljenje, modifi cirana shema ________________________________________________________________________________________
